Filter Results :

Your search for Lymphoma returned 97 reports

Sort by


Global Hodgkin’s Lymphoma Therapeutics Market Research Report 2017

06 Feb 2017  |  Published by:  9Dimen Research
Hodgkin’s Lymphoma Therapeutics Report by Material, Application, and Geography - Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (Unite...

$ 2,850.00
$ 2,565.00
( Save 10% )

Read More

Global Non-Hodgkin Lymphoma Therapeutics Market Research Report 2017

06 Feb 2017  |  Published by:  9Dimen Research
Non-Hodgkin Lymphoma Therapeutics Report by Material, Application, and Geography - Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (Uni...

$ 2,850.00
$ 2,565.00
( Save 10% )

Read More

Global Lymphoma Partnering 2010 to 2017

01 Feb 2017  |  Published by:  CurrentPartnering
The Global Lymphoma Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world’s leading healthcare companies. • Trends in partnering deals • Top deals by value • Deals lis...

$ 1,495.00

Read More

Global Non-Hodgkin Lymphoma Partnering 2010 to 2017

01 Feb 2017  |  Published by:  CurrentPartnering
The Global Non-Hodgkin Lymphoma Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world’s leading healthcare companies. • Trends in partnering deals • Top deals by value ...

$ 1,495.00

Read More

Non-Hodgkin Lymphoma - Heat Map and Analysis

06 Jan 2017  |  Published by:  GBI Research
SummaryNon-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. There were an estimated 385,741 new cases of NHL and 199,630 deaths from NHL worldwide in 2012. NHLs are classified as either indolent (slow...

$ 2,000.00

Read More

Anaplastic Large Cell Lymphoma (ALCL)-Pipeline Insights, 2017

01 Jan 2017  |  Published by:  DelveInsight
Anaplastic Large Cell Lymphoma (ALCL)-Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Anaplastic Large Cell Lymphoma (ALCL). The DelveInsightsReport covers the product profiles in various stages of development including Dis...

$ 1,250.00

Read More

B-Cell Lymphomas-Pipeline Insights, 2017

01 Jan 2017  |  Published by:  DelveInsight
B-Cell Lymphomas-Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the B-Cell Lymphomas. The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase ...

$ 1,250.00

Read More

B-Cell Non-Hodgkin Lymphoma-Pipeline Insights, 2017

01 Jan 2017  |  Published by:  DelveInsight
B-Cell Non-Hodgkin Lymphoma-Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the B-Cell Non-Hodgkin Lymphoma. The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-clinical...

$ 1,250.00

Read More

Cutaneous T-Cell Lymphoma-Pipeline Insights, 2017

01 Jan 2017  |  Published by:  DelveInsight
Cutaneous T-Cell Lymphoma-Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Cutaneous T-Cell Lymphoma. The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IN...

$ 1,250.00

Read More

Indolent Lymphoma-Pipeline Insights, 2017

01 Jan 2017  |  Published by:  DelveInsight
Indolent Lymphoma-Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Indolent Lymphoma. The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phas...

$ 1,250.00

Read More

Lymphoblastic Lymphoma-Pipeline Insights, 2017

01 Jan 2017  |  Published by:  DelveInsight
Lymphoblastic Lymphoma-Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Lymphoblastic Lymphoma. The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Pha...

$ 1,250.00

Read More

Peripheral T-Cell Lymphomas (PTCL)-Pipeline Insights, 2017

01 Jan 2017  |  Published by:  DelveInsight
Peripheral T-Cell Lymphomas (PTCL)-Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Peripheral T-Cell Lymphomas (PTCL). The DelveInsightsReport covers the product profiles in various stages of development including Discovery...

$ 1,250.00

Read More

T-Cell Lymphomas-Pipeline Insights, 2017

01 Jan 2017  |  Published by:  DelveInsight
T-Cell Lymphomas-Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the T-Cell Lymphomas. The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase ...

$ 1,250.00

Read More

Hodgkin Lymphoma-API Insights, 2017

01 Jan 2017  |  Published by:  DelveInsight
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API ...

$ 1,250.00

Read More

Lymphoma-API Insights, 2017

01 Jan 2017  |  Published by:  DelveInsight
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API ...

$ 1,250.00

Read More
Total 97 records.